Novavax Hits Profit in Q4 2025 & Raises 2026 Revenue Forecast
Novavax reports strong 2025 results, first Q4 profit in years, and boosts 2026 outlook thanks to Pfizer & Sanofi deals.
/ 20 items
#SNY↓
William Blair Upgrades Nektar on Strong Rezpeg Drug Data
William Blair upgrades Nektar to Outperform following promising long-term data for rezpegaldesleukin in atopic dermatitis treatment with improved safety profile. The results met and in some cases exceeded investor expectations.
Sanofi Pursues Enhanced Bid for US Biotech Ocular Therapeutix
French pharma giant Sanofi is preparing an improved takeover offer for Ocular Therapeutix after its initial $16-per-share proposal was rejected by the biotech's board.
FDA Delays Decisions on Lilly's Obesity Pill and Other Fast-Track Drug Reviews
FDA extends review timelines for Eli Lilly's obesity pill Orforglipron and three other priority voucher drugs, despite promises of accelerated 1-2 month reviews under new program.
Sanofi Acquires Dynavax for $2.2 Billion to Boost Vaccine Portfolio
French drugmaker Sanofi agrees to purchase U.S. vaccines company Dynavax Technologies for $2.2 billion, gaining access to hepatitis B vaccine and experimental shingles shot.
Trump Administration Secures Drug Price Cuts from Nine Major Pharmaceutical Companies
Nine pharmaceutical giants including Merck and GSK agree to slash U.S. drug prices to match other wealthy nations under new Trump administration deals, offering discounts up to 70%.